Tagir R. Gizatullin
Tagir R. Gizatullin has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandr M. Reznik
Mental-health clinic No. 1 named after N.A. Alexeev
1 shared publication - Aleksandr V. Mudrak
Mental-health Clinic No. 1 named after N.A. Alexeev, Moscow
1 shared publication - Anastasia O. Vasilenko1 shared publication
- Anastasiia E. Abdrakmanova
Bashkir State Medical University; Republican Clinical Psychotherapy Center
1 shared publication - Anton Nikolaevich Gvozdetsky
North-Western State Medical University Named After I.I. Mechnikov
1 shared publication - Artur Tukhvatullin
Institute of Biochemistry and Genetics of the Russian Academy of Sciences, pr. Oktyabrya, 71, Ufa, 450054, Russian Federation
1 shared publication
Latest Publications
- 21 April 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (4) , 120-124
A clinical case of multiple sclerosis with an episode of schizophrenia-like syndrome
The article presents a clinical observation of a schizophrenia-like disorder in a patient with multiple sclerosis (MS). The patient had highly active MS with a relapsing course, the diagnosis was made based on the McDonald 2017 criteria. During the course of a demyelinating disease of the nervous system, the patient developed an episode of psychotic disorders with symptoms of mutism, hallucinations, delusions and impaired thinking, which was quickly stopped in stationary conditions. This case is of particular interest to neurologists and psychiatrists, since psychotic disorders occur in MS patients and cause difficulties in diagnosis and treatment.
- 21 April 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (4) , 120-124
A clinical case of multiple sclerosis with an episode of schizophrenia-like syndrome
The article presents a clinical observation of a schizophrenia-like disorder in a patient with multiple sclerosis (MS). The patient had highly active MS with a relapsing course, the diagnosis was made based on the McDonald 2017 criteria. During the course of a demyelinating disease of the nervous system, the patient developed an episode of psychotic disorders with symptoms of mutism, hallucinations, delusions and impaired thinking, which was quickly stopped in stationary conditions. This case is of particular interest to neurologists and psychiatrists, since psychotic disorders occur in MS patients and cause difficulties in diagnosis and treatment.
- Open Access
- 30 September 2022
- Published by ECO-Vector LLC in Consortium Psychiatricum
- Vol. 3 (3) , 58-72
Clinical Effectiveness of Lurasidone Monotherapy in Patients with Acute Episodes of Schizophrenia and Associated Symptoms of Depression
AIM: We endeavored to evaluate the efficacy of Lurasidone at doses of 40160 mg per day on symptoms of schizophrenia associated with symptoms of depression in real clinical practice in a Russian patient population. METHODS: One hundred sixty eight patients aged 1865 years old, who at the time of the start of the observation were being treated in a hospital or day hospital due to an exacerbation of paranoid schizophrenia accompanied by symptoms of depression, were prescribed lurasidone. Treatment with lurasidone and other concomitant drugs, their prescription, withdrawal, selection, and dose modifications were determined based on the indications for the use of those drugs and the recommended doses in the instructions, clinical need, and patient interests, rather than by the goals of the study. During the observation period, the severity of depressive symptoms according to the Calgary Depression Scale (CDSS) and that of psychotic symptoms according to the Positive and Negative Syndrome Scale (PANSS) were assessed six times (before the start of treatment and then on the 4th, 7th, 14th, 28th, and 42nd days). RESULTS: A statistically significant reduction in the severity of the symptoms was observed with the use of lurasidone in doses ranging from 40 mg to 160 mg per day. The fastest and most significant (p 0.001) reductions in the total PANSS and CDSS scores were observed with lurasidone 120 mg. A somewhat lower efficacy of lurasidone was observed at a dose of 160 mg. The largest reductions in the total PANSS and CDSS scores with lurasidone 120 mg were associated with the highest survival rate and the longest median time from treatment initiation to discontinuation or follow-up. The most commonly reported side effects with lurasidone in this study (nausea, akathisia, tremor and drowsiness) were consistent with the known safety profile of the drug. Adverse events in most cases were assessed as mild, or occasionally moderate. CONCLUSION: A six-week prospective observational study of the real-world clinical effectiveness of lurasidone in doses ranging from 40 mg to 160 mg per day established statistically and clinically significant improvements in both psychotic and depressive symptoms in patients with acute exacerbation of schizophrenia and associated symptoms of depression.
- 30 September 2022
- Published by ECO-Vector LLC in Consortium Psychiatricum
- Vol. 3 (3) , 58-72
Open AccessClinical Effectiveness of Lurasidone Monotherapy in Patients with Acute Episodes of Schizophrenia and Associated Symptoms of Depression
AIM: We endeavored to evaluate the efficacy of Lurasidone at doses of 40160 mg per day on symptoms of schizophrenia associated with symptoms of depression in real clinical practice in a Russian patient population. METHODS: One hundred sixty eight patients aged 1865 years old, who at the time of the start of the observation were being treated in a hospital or day hospital due to an exacerbation of paranoid schizophrenia accompanied by symptoms of depression, were prescribed lurasidone. Treatment with lurasidone and other concomitant drugs, their prescription, withdrawal, selection, and dose modifications were determined based on the indications for the use of those drugs and the recommended doses in the instructions, clinical need, and patient interests, rather than by the goals of the study. During the observation period, the severity of depressive symptoms according to the Calgary Depression Scale (CDSS) and that of psychotic symptoms according to the Positive and Negative Syndrome Scale (PANSS) were assessed six times (before the start of treatment and then on the 4th, 7th, 14th, 28th, and 42nd days). RESULTS: A statistically significant reduction in the severity of the symptoms was observed with the use of lurasidone in doses ranging from 40 mg to 160 mg per day. The fastest and most significant (p 0.001) reductions in the total PANSS and CDSS scores were observed with lurasidone 120 mg. A somewhat lower efficacy of lurasidone was observed at a dose of 160 mg. The largest reductions in the total PANSS and CDSS scores with lurasidone 120 mg were associated with the highest survival rate and the longest median time from treatment initiation to discontinuation or follow-up. The most commonly reported side effects with lurasidone in this study (nausea, akathisia, tremor and drowsiness) were consistent with the known safety profile of the drug. Adverse events in most cases were assessed as mild, or occasionally moderate. CONCLUSION: A six-week prospective observational study of the real-world clinical effectiveness of lurasidone in doses ranging from 40 mg to 160 mg per day established statistically and clinically significant improvements in both psychotic and depressive symptoms in patients with acute exacerbation of schizophrenia and associated symptoms of depression.
- Open Access
- 11 April 2022
- Published by ECO-Vector LLC in Neurology Bulletin
- Vol. LIV (1) , 63-71
Dysfunctional use of social networks: can we talk about addiction?
The article presents materials from Russian and foreign literature indicating the similarity between certain types of behavior in social networks and addictive behavior, as well as demonstrating the negative consequences of problematic use of social networks for the physical, mental and social well-being of users. Biological, personal and social factors predisposing to problematic use of social networks are considered. The data on the comorbidity of social media addiction with other types of addiction behavior and mental disorders, such as technological, eating, consumer addiction, depression, mania, anxiety disorder, episodes of psychotic-like experiences are presented.
- 11 April 2022
- Published by ECO-Vector LLC in Neurology Bulletin
- Vol. LIV (1) , 63-71
Open AccessDysfunctional use of social networks: can we talk about addiction?
The article presents materials from Russian and foreign literature indicating the similarity between certain types of behavior in social networks and addictive behavior, as well as demonstrating the negative consequences of problematic use of social networks for the physical, mental and social well-being of users. Biological, personal and social factors predisposing to problematic use of social networks are considered. The data on the comorbidity of social media addiction with other types of addiction behavior and mental disorders, such as technological, eating, consumer addiction, depression, mania, anxiety disorder, episodes of psychotic-like experiences are presented.